Exelon data

Sandoz reported positive preliminary results from four pivotal trials involving more than 3,300 patients. The company reported data from a six-month, double-blind, placebo-controlled U.S. trial in 699 patients with mild to moderately severe Alzheimer's dementia. High and low doses were compared with placebo.

Treatment was discontinued due to side effects in 25 percent of treated patients versus 16 percent on placebo. The most common side effects of Exelon were nausea, vomiting, diarrhea, loss of appetite, dizziness and fatigue. ...